29/07/2016 11:09:35 Cookie Policy +44 (0) 207 0700 961 Free Membership Login
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 15.625p 15.25p 16.00p - - - 2,137 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 30.0 -15.8 -8.8 - 72.54

Ekf Diagnostics (EKF) Latest News

More Ekf Diagnostics News
Ekf Diagnostics Takeover Rumours

Ekf Diagnostics (EKF) Share Charts

1 Year Ekf Diagnostics Chart

1 Year Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart

Intraday Ekf Diagnostics Chart

Intraday Ekf Diagnostics Chart

Ekf Diagnostics (EKF) Discussions and Chat

Ekf Diagnostics (EKF) Top Chat Posts

DateSubject
29/7/2016
09:20
Ekf Diagnostics Daily Update: Ekf Diagnostics is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 15.63p.
Ekf Diagnostics has a 4 week average price of 14.68p and a 12 week average price of 12.69p.
The 1 year high share price is 23.50p while the 1 year low share price is currently 0p.
There are currently 464,262,781 shares in issue and the average daily traded volume is 624,397 shares. The market capitalisation of Ekf Diagnostics is £72,541,059.53.
20/7/2016
11:58
andrewbaker: The recent share purchase (see news articles on quotes page) suggests that the company is prospering/will prosper greatly going forward. The weakness of the £ sterling combined with sales in US$ and other currencies is a big boost for many British businesses; and if their core product(s) are improving in sales/prospects too, that's a double bonus. A continuing rise in the EKF share price looks very much on the cards right now and going forward.
06/7/2016
07:16
wan: An encouraging and upbeat Trading Update today, as well as clarifying that Brexit will have no effect on sales - "the Board notes that it does not anticipate any impact to sales from the forthcoming decoupling of the United Kingdom from the European Union. EKF sales into EU countries are derived entirely from offices within the EU and US, with no such sales made from the UK and therefore global sales are not expected to be impacted." http://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Trading-Update/71899624
12/4/2016
09:44
cisk: With his shareholding and loan to the company I don't think it's over with him at all, in fact I'm surprised he resigned. I'm also surprised with the share price reaction today - i.e. it's gone up. It's very clear there's an awful lot of work to do, both in terms of restoring management credibility and actually making a proper profit. Currently all the share price offers is hope. My fingers have been burnt on this one in the past, I'd rather buy back at a higher price, after tangible evidence of progress on the bottom line is evident.
04/4/2016
11:09
wan: I am not suggesting that the postponement of the Results by a week is anything to do with the following, it's just food for thought; Some might recall that as reported by EKF, http://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Strategic-Update/69002271 RZ is also currently Chairman and Chief Executive Officer of Lumira Holdings Ltd. But what interested me more was the connected business Lumira Diagnostics Ltd. I further noticed the following job vacancy description, which was posted in December 2015 (no other job listings state that Multi-Sense is a subsidiary of Lumira) - Engineering And Manufacturing Manager in Lumira Diagnostics (UK) Multi-Sense, a subsidiary of Lumira, are a young and energetic company developing revolutionary and flexible assay platform technologies that will transform In Vitro Diagnostic testing and provide next generation healthcare. The company was founded in 2009 and is located at our newly built facility in Stirling. We are looking for a proactive, talented, focused and enthusiastic individual who can make a significant contribution to the continued growth and success of our company. (end) Revolutionary and transforming have big meanings, but are obviously just words at present and there may be no connection and just a typo. RZ is not listed as a director at Multi-Sense, however, his fellow directors at Lumira, Dr David Scott and Dr Jerome Francis Francis Mcaleer, are both directors at Muti-Sense. Very recently, and apparently as a result of growth, Multi-Sense Technologies have posted quite a few vacancies - March 2016: Due to continued growth, we are currently recruiting for a variety of roles as shown below: http://mst-uk.com/News.html Multi-Sense and Lumira are still listed as a private independent companies, but that does not mean that that is still the case as Companies House will get updated at the next filing date. I also noticed that the following individual has apparently done some work for Lumira - Richard R. Kelly Rich concentrates on cross-border and domestic M&A representation and corporate fiduciary counseling. He co-heads the firm’s International Practice. Lumira Holdings Ltd in its expatriation to the U.K. and in connection with its private placements and acquisitions of connected health companies. https://www.mintz.com/professionals/detail/name/richard-r-kelly RZ has quite a bit of history and connection with companies/deals in Scotland. Thus it will be interesting to see what materializes, or indeed if there is any connection formed with Lumira and/or multi-Sense.
08/11/2015
23:45
cisk: Inter, talk is cheap and these guys have been paid handsomely for their efforts - or lack of. Anyone can apologise - indeed I've witnessed this first hand several times from these guys; it will take more than talk to get this share price up.
06/11/2015
16:11
cisk: all, tbh I would expect the likes of Baines et al to be buying shares in the market at the current level. If they can't announce sales etc then thats the only option to shore up confidence. Assuming they could of course... I'm thoroughly disappointed in this whole episode - after hearing them discuss the tech, pipeline and opportunities at length many times I'm seriously surprised we're where we are. The much-trumpeted sales to Mexico for example have not been announced. Nor do I hold out hope of RZ coming to the rescue at a price anywhere near what we would find appetising. He didn't make a fortune by being generous to shareholders of companies he wants to acquire. Wan, I know you thought 10p was wide of the mark, but if RZ spots an opportunity to buy the whole lot, spin off the molecular division on nasdaq in 6 months and develop the diagnostic side, he'll take it and pay the minimum to do so. And the institutions that bought around 40p if memory serves would probably be glad to get this company off their books at 10p as it's unlikely they could shift any serious volume of stock without collapsing the share price even more from current levels. what the company is actually worth is anyone's guess. Probably what RZ is prepared to pay as so far he looks like the only person who might buy the company.
02/11/2015
10:59
kestelmill: My hunch is this: -RZ sees this company as his next vehicle -RZ strategy will be as per his normal strategy - become major global Dx player via acquisition -RZ is fairly well aligned with DE/JB on strategy -Hence when DE/JB were challenged by major shareholders they saw RZ chairmanship as a good fall back option -They now have carte blanche to progress, at least for the time being. A bit like when a football club appoints a new manager - they've got a reasonable period to succeed. -Major shareholders will realise this and if it doesn't fit with their investment approach (risk, etc) they will bail out. This is happening now hence share price going down. -I wouldn't be surprised if RZ becomes CEO. It depends on his relationship with JB and how many shares he buys. -All depends on RZ now. Not such a bad horse to back but share price likely to go down before it recovers.
28/10/2015
07:54
interstellar: Yes Bigman- my point entirely. No one objects (least of all me) to competitive salaries but they come with responsibility to deliver and this is outrageous non-performance. Way too cozy. The bottom line would look healthier without these expenses and it is us shareholders that are paying for it. Personally, with no positive evidence to the contrary, I think the year end is going to be awful. There has been little or no improvement in the exchange rate (if anything the pound is stronger) especially against the rouble meaning that accounts are going to take a hit again. There has been no announcement of big contracts won as heralded at the half way stage and here we are in week 44. A potential suitor has performed extensive due diligence and walked away from the negotiation table (not a good sign when the company has lifted its skirts to show all) and the share price has taken a big hit. And the institutional investors are losing patience. Brace yourselves.
25/6/2015
08:59
cisk: Morning Wan Agree - Mgt will be judged on next month's update - but as we both know, it takes a long time to gain any sort of traction in diagnostics - in fact anything healthcare related - as my small holding in Deltex will attest to! Very interesting news re: Alere; given the already strong relationship between them and Ron's shareholding in both companies it would not be a surprise. However I'm in it for the long term and believe that the share price can be at multiples of its current level, so personally I wouldn't want to see them taken over at a price anywhere near the current share price. Hopefully patience will be my biggest ally...
08/5/2014
10:20
totaleclipse: Just to put in a tiny bit more information I heard that Selah sales people were being paid very high commissions per test to incentivize them. Like half! That's kind of excessive dont you think? If the reimbursers discovered that bit of information I would guess they would be less than happy as it suggests the margins are very wide and maybe the reason for the cut. >>Bigman. You spotted a good point. If we focus on the next driver for the EKF share price- i.e. the 6 months results, the sales will be enhanced by just the $0.5m you calculate for April and a further $1.5m for May and June- not sure if that is going to reignite the shares to recover their upward path. Anyone have any views on the 6 month numbers?

Ekf Diagnostics (EKF) Latest Trade

Ekf Diagnostics Most Recent Trade

Trade Type Trade Size Trade Price Trade Date Trade Time Currency
O 2,137 15.70 29 Jul 2016 09:14:16 GBX
Ekf Diagnostics share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20160729 10:09:35